Welcome to Action Kidney Cancer

The United Kingdom’s only patient-led kidney cancer charity

Steve shares his experience of living with kidney cancer

Join our patient support forum for friendly patient-to-patient support and advice

Learn about Action Kidney Cancer’s patient services

Newly diagnosed with kidney cancer

Kidney cancer treatments

Fundraising

Patient Support Forum

Stronger together

In our own words

During this series of videos, kidney cancer patients and carers talk frankly about their experiences, emotions and how to live well with a diagnosis of kidney cancer
Coping with a diagnosis of kidney cancer
Talking about kidney cancer
A carer’s perspective

Real stories

The lives of all these people have been affected by kidney cancer
Some are patients, some are carers, all are stories by real people sharing their experiences of living with kidney cancer

Latest kidney cancer news

12 Sep 2024

89Zr-DFO-girentuximab for PET/CT imaging of kidney cancer

Read More

6 Sep 2024

Intermittent immunotherapy in patients with metastatic kidney cancer

Read More

6 Sep 2024

Patient perspectives on reduced treatment schedules for immunotherapy

Read More

5 Sep 2024

Belzutifan available on the NHS for patients with VHL disease

Read More

5 Sep 2024

The Big Cancer52 Conversation

Read More

4 Sep 2024

Belzutifan compared to everolimus for advanced kidney cancer

Read More

2 Aug 2024

Exercise may improve quality of life for kidney cancer patients

Read More

15 Jul 2024

Cancer waiting times: latest updates

Read More

15 Jul 2024

WECAN Academy 2024

Read More

10 Jul 2024

FDA grant fast track status to CAR T cell therapy for kidney cancer

Read More

1 Jul 2024

Perioperative nivolumab in intermediate/high risk kidney cancer patients

Read More

20 Jun 2024

Why the next UK Government must set out a new strategy for cancer

Read More

Action Kidney Cancer

Friendship...community...encouragement...advocacy...information...support...kindness...advice...shared experiences...patient stories...research news...expert insights...empowerment...
Action Kidney Cancer
Action Kidney Cancer19 hours ago
Researchers are looking for better ways to diagnose kidney cancer. Currently, diagnosis is made using scans, which cannot tell the difference between benign and cancerous tumours. For a more accurate diagnosis, a biopsy involving surgery may be needed. There is, therefore, an unmet need for an accurate test to diagnose kidney cancer to guide patient management.

Girentuximab is an antibody that attaches to an enzyme called carbonic anhydrase IX (CAIX). This enzyme is found in clear cell kidney cancer tumours. 89Zr-DFO-girentuximab (TLX250-CDx) is a product made from combining a weakly radioactive molecule called zirconium Zr 89 with girentuximab. When given to humans, 89Zr-DFO-girentuximab binds to carbonic anhydrase IX in kidney cancer tumours and can help to tell the difference between kidney cancer, normal tissue, and other tumours.

Read more on our website here:
Action Kidney Cancer
89Zr-DFO-girentuximab for PET/CT imaging of kidney cancer - Action Kidney Cancer
TLX250-CDx is a product made from combining a weakly radioactive molecule with an antibody. When given to humans, TLX250-CDx binds to an enzyme in kidney cancer tumours and can help diagnose kidney cancer. Findings from a clinical trial looking at TLX250-CDx in patients have been published.
1View on Facebook
Action Kidney Cancer
Action Kidney Cancer2 days ago
Join the Cut and Share, I did it for you event!

@Clinical Net have invited us to be part of their event to help raise awareness and funds for research and to help cancer patients.

The event is taking place from the 12th to the 14th September at Jubilee Place, Canary Wharf, London E14 5NY.

During the event they are inviting the public to cut or shave off a significant portion of their hair, the donated hair will be used to make wigs for patients.

Each participant will receive a personalised video capturing their brave before and after moments with the caption 'I did it for you' which they can share on their social media.

If you would like to get involved please contact fundraising@actionkidneycancer.org or if you would like to make a donation, please follow the link below:

https://kcsn.enthuse.com/cf/cut-and-share

#KidneyCancer #bypatientsforpatients #StrongerTogether

#CutandShare #IDidItForYou
Action Kidney Cancer
');jQuery( ".feed_dynamic_video_classznrmtugpwp_page .fts-greater-than-width-height.fts-fb-video-on-page, .feed_dynamic_video_classznrmtugpwp_page iframe" ).css({"height": "405px", "width": "720px"});});});
View on Facebook
Action Kidney Cancer
Action Kidney Cancer7 days ago
The combination of ipilimumab plus nivolumab is approved for patients as a first-line treatment for metastatic kidney cancer. But duration of treatment and the safety or effectiveness of re-starting treatment when the cancer progresses is not known. This is a phase 2 clinical trial looks at the use of intermittent ipilimumab plus nivolumab and re-starting treatment when the cancer progresses.

Read more on our website here:
Action Kidney Cancer
Intermittent immunotherapy in patients with metastatic kidney cancer - Action Kidney Cancer
The combination of ipilimumab plus nivolumab is approved for patients as a first-line treatment for metastatic kidney cancer. But duration of treatment and the safety or effectiveness of re-starting treatment when the cancer progresses is not known. This is a phase 2 clinical trial looks at the use....
1View on Facebook
Action Kidney Cancer
Action Kidney Cancer7 days ago
We are really pleased that the OPTIC study has now been published in the British Journal of Cancer. OPTIC was looking at patient and carer’s perspectives of trials for reduced treatment schedules for immunotherapy.

Alison Fielding, Trustee for Action Kidney Cancer, and Sharon Deveson Kell, Policy and Medical Affairs for Action Kidney Cancer, are both authors of this paper.

Read more on our website here:
Action Kidney Cancer
Patient perspectives on reduced treatment schedules for immunotherapy - Action Kidney Cancer
Immunotherapy has transformed the treatment of many cancers, including kidney cancer and melanoma. Clinical trials are looking at reduced treatment schedules for immunotherapy with the aim of improving quality of life, tolerability, and cost-effectiveness. This study aims to provide insight into pat...
View on Facebook
Action Kidney Cancer
Action Kidney Cancer1 week ago
We are delighted to announce that the National Institute for Health and Care Excellence (NICE) has issued final draft guidance for use of the HIF-2α inhibitor, belzutifan, for the treatment of people with von Hippel-Lindau (VHL) renal cell carcinoma (RCC) who do not need or want surgery. Belzutifan is approved for use by NHS England under a managed access scheme. Belzutifan meets an unmet treatment need for people with VHL disease.

Read more on our website here:
Action Kidney Cancer
Belzutifan available on the NHS for patients with VHL disease - Action Kidney Cancer
We are delighted to announce that the National Institute for Health and Care Excellence (NICE) has issued final draft guidance for use of the HIF-2α inhibitor, belzutifan, for the treatment of people with von Hippel-Lindau (VHL) renal cell carcinoma (RCC) who do not need or want surgery. Belzutifan...
View on Facebook
Action Kidney Cancer
Action Kidney Cancer1 week ago
A new medicine called belzutifan is a tablet that blocks cancer cell growth. In this study, belzutifan is compared with everolimus as a treatment for people with advanced kidney cancer who have already received treatment for their cancer.

Belzutifan showed a significant benefit over everolimus with respect to progression-free survival and response to treatment in previously treated patients with advanced kidney cancer.

Red more on our website here:
Action Kidney Cancer
Belzutifan compared to everolimus for advanced kidney cancer - Action Kidney Cancer
A new medicine called belzutifan is a tablet that blocks the action of HIF-2α and, therefore, blocks cancer cell growth. There were 746 patients enrolled in this phase 3 clinical trial, called LITESPARK-005. 374 patients were treated with belzutifan, and 372 with everolimus.
1View on Facebook
[php_everywhere instance="3"]